Content |
Biography
2024: Appointment as CEO of Veropharm
In January 2024, Maria Zazulevskaya became the new CEO of Veropharm. She replaced Ivan Polyak, who headed the manufacturer of drugs since 2019. He was also Senior Director for Commercial Development, Strategy and Sales of Abbott's drug division at the company's head office.
Ivan Polyak, in turn, was appointed General Director and President of Novartis Pharma LLC. Natalya Kolerova, who previously held these positions, moved to another role in the company in the European region.
By January 2024, Veropharm, part of the Abbott group, operates production sites in the Vladimir region, Belgorod and Voronezh. The company also has a scientific and technical production center in Belgorod. Veropharm is engaged in the production of oncological drugs, drugs used to treat gastroenterological, gynecological, infectious diseases, as well as used in dermatology and neurology. Enterprises also produce medical products. In total, the company's production portfolio includes over 200 products.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |